{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:00:05Z","timestamp":1780563605596,"version":"3.54.1"},"reference-count":38,"publisher":"CSIRO Publishing","issue":"6","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pre-exposure prophylaxis (PrEP) use could be accelerated by offering alternatives that overcome key barriers associated with oral PrEP. This study aimed to understand willingness and preferences for long-acting injectable cabotegravir (CAB-LA) among gay men and other men who have sex with men (MSM), and transgender women (TGW) in Asia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An online cross-sectional survey was conducted from May to November 2022 among HIV-negative or unknown status MSM and TGW aged \u226518\u00a0years across 15 and 11 Asian countries\/territories, respectively. Survey items included awareness and use of PrEP and CAB-LA, willingness to use current and emerging PrEP options, and attitudes towards CAB-LA. Descriptive statistics and logistic regression were used to analyse associations with willingness to use CAB-LA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 11,870 MSM and 980 TGW, 21.4% (n\u00a0=\u00a02448) and 32.5% (n\u00a0=\u00a0295) were aware of CAB-LA, respectively, and 17.2% (n\u00a0=\u00a02036) and 16.8% (n\u00a0=\u00a0165) were willing to use it. CAB-LA was the most preferred PrEP option for 3.6% (n\u00a0=\u00a0400) of MSM and 6.5% (n\u00a0=\u00a061) of TGW. Awareness and willingness varied across countries\/territories and populations. Key benefits of CAB-LA included HIV protection (57.8% MSM, 46.8% TGW), no need for daily pills (42.6% MSM, 31.1% TGW) and longer-term protection (38.0% MSM, 23.6% TGW). Main concerns included cost (39.6% MSM, 22.1% TGW), side-effects (37.5% MSM, 22.2% TGW), insufficient knowledge (33.3% MSM, 20.6% TGW) and pain (21.4% MSM, 24.9% TGW).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Successful introduction of CAB-LA, or other new long-acting injectable PrEP options, in Asia will require strategies to raise awareness and demand-generation that responds to the perceived benefits and concerns of communities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh25065","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T02:49:36Z","timestamp":1761792576000},"source":"Crossref","is-referenced-by-count":2,"title":["Preparing for next-generation PrEP: awareness and willingness to use long-acting injectable cabotegravir among men who have sex with men and trans women across Asia"],"prefix":"10.1071","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-6407","authenticated-orcid":true,"given":"Heather-Marie A.","family":"Schmidt","sequence":"first","affiliation":[{"name":"AUNAIDS, Geneva, Switzerland."},{"name":"BWorld Health Organization, Avenue Appia, Geneva 1211, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9581-1011","authenticated-orcid":true,"given":"Curtis","family":"Chan","sequence":"additional","affiliation":[{"name":"CKirby Institute, UNSW Sydney, Sydney, NSW, Australia. Email: cchan@kirby.unsw.edu.au; bbavinton@kirby.unsw.edu.au"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polin","family":"Ung","sequence":"additional","affiliation":[{"name":"DUNAIDS office for Cambodia, Lao PDR and Malaysia, Phnom Penh, Cambodia. Email: ungp@unaids.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiara","family":"Nisa","sequence":"additional","affiliation":[{"name":"EWHO Western Pacific Regional Office, Manila, the Philippines. Email: nisat@who.int"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-7403","authenticated-orcid":true,"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[{"name":"FMelbourne Sexual Health Centre, Alfred Health, Melbourne, Vic, Australia. Email: Jong@mshc.org.au, wtieosapjaroen@mshc.org.au"},{"name":"GSchool of Translational Medicine, Monash University, Melbourne, Vic, Australia. Email: lei.zhang1@monash.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-9262","authenticated-orcid":true,"given":"Warittha","family":"Tieosapjaroen","sequence":"additional","affiliation":[{"name":"FMelbourne Sexual Health Centre, Alfred Health, Melbourne, Vic, Australia. Email: Jong@mshc.org.au, wtieosapjaroen@mshc.org.au"},{"name":"GSchool of Translational Medicine, Monash University, Melbourne, Vic, Australia. Email: lei.zhang1@monash.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0848-8480","authenticated-orcid":true,"given":"Kimberly E.","family":"Green","sequence":"additional","affiliation":[{"name":"HPATH, Hanoi, Vietnam. Email: kgreen@path.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0036-3165","authenticated-orcid":true,"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[{"name":"IInstitute of HIV Research and Innovation, Bangkok, Thailand. Email: nittaya.p@ihri.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Cassell","sequence":"additional","affiliation":[{"name":"JFHI 360, Atlanta, GA, USA. Email: mcassell@fhi360.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Suwandi","sequence":"additional","affiliation":[{"name":"KAPCOM, Bangkok, Thailand. Email: Nickys@apcom.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Boonyapisomparn","sequence":"additional","affiliation":[{"name":"LSisters Foundation, Pattaya, Thailand. Email: huab2007@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midnight","family":"Poonkasetwattana","sequence":"additional","affiliation":[{"name":"KAPCOM, Bangkok, Thailand. Email: Nickys@apcom.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-084X","authenticated-orcid":true,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"GSchool of Translational Medicine, Monash University, Melbourne, Vic, Australia. Email: lei.zhang1@monash.edu"},{"name":"MArtificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic, Australia. Email: midnightp@apcom.org"},{"name":"NPhase I Clinical Trial Research Ward, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, No.157 Xi Wu Road, Xi\u2019an 710004, Shaanxi Province, PR China."},{"name":"OChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi\u2019an Jiaotong University Health Science Center, Xi\u2019an 710061, Shaanxi, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-8278","authenticated-orcid":true,"given":"Benjamin R.","family":"Bavinton","sequence":"additional","affiliation":[{"name":"CKirby Institute, UNSW Sydney, Sydney, NSW, Australia. Email: cchan@kirby.unsw.edu.au; bbavinton@kirby.unsw.edu.au"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2025111816250493000_R1","unstructured":"UNAIDS. The urgency of now: AIDS at a crossroads. Geneva: Joint United Nations Programme on HIV\/AIDS; 2024."},{"issue":"1S","key":"2025111816250493000_R2","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1097\/QAI.0000000000003340","article-title":"New HIV infections among key populations and their partners in 2010 and 2022, by world region: a multisources estimation.","volume":"95","author":"Korenromp","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025111816250493000_R3","unstructured":"UNAIDS. 2024 epidemiological estimates: trend of new HIV infections (Philippines). UNAIDS; 2024. Available at https:\/\/aidsinfo.unaids.org?did=5b4eaa7cdddb54192bb39714&r=world&t=2023&tb=m&bt=mnli&ts=32,0&ml=2&mt=1"},{"key":"2025111816250493000_R4"},{"issue":"12","key":"2025111816250493000_R5","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis.","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"issue":"8","key":"2025111816250493000_R6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2023.9865","article-title":"Pre-exposure prophylaxis for the prevention of HIV infection: a systematic review for the U.S. preventive services task force.","volume":"330","author":"Chou","year":"2023","journal-title":"JAMA"},{"key":"2025111816250493000_R7","unstructured":"UNAIDS. 2024 epidemiological estimates. UNAIDS; 2024. Available at https:\/\/aidsinfo.unaids.org\/"},{"key":"2025111816250493000_R8","unstructured":"PrEP Watch. Global PrEP Tracker: AVAC; 2024. Available at https:\/\/data.prepwatch.org\/"},{"key":"2025111816250493000_R9"},{"issue":"6","key":"2025111816250493000_R10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","article-title":"Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.","volume":"37","author":"Fonner","year":"2023","journal-title":"AIDS"},{"issue":"10337","key":"2025111816250493000_R11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"2025111816250493000_R12","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/S2352-3018(23)00261-8","article-title":"Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.","volume":"10","author":"Landovitz","year":"2023","journal-title":"Lancet HIV"},{"issue":"6","key":"2025111816250493000_R13","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26118","article-title":"Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.","volume":"26","author":"Donnell","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"2025111816250493000_R14","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25963","article-title":"Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice.","volume":"25","author":"Schmidt","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2025111816250493000_R15","doi-asserted-by":"publisher","DOI":"10.1071\/SH23192","article-title":"Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia.","volume":"21","author":"Bavinton","year":"2024","journal-title":"Sex Health"},{"issue":"11","key":"2025111816250493000_R16","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s10461-023-04093-1","article-title":"The future of pre-exposure prophylaxis (PrEP) for HIV prevention: a global qualitative consultation on provider perspectives on new products and differentiated service delivery.","volume":"27","author":"Henderson","year":"2023","journal-title":"AIDS Behav"},{"key":"2025111816250493000_R17","unstructured":"AVAC. A quarterly update from the Secretariat of the Coalition to Accelerate Access to Long-Acting PrEP: Long-Acting PrEP Status as of April 2024. AVAC; 2024."},{"key":"2025111816250493000_R18","unstructured":"Viiv Healthcare. Worldwide Registration: cabotegravir PrEP. Viiv Healthcare; 2025. Available at https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viivhealthcare\/en_GB\/pdf\/wwrs-for-external-use.pdf"},{"issue":"Suppl 2","key":"2025111816250493000_R19","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26107","article-title":"Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.","volume":"26","author":"Lorenzetti","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"2025111816250493000_R20","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2352-3018(24)00235-2","article-title":"Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension.","volume":"11","author":"Kamya","year":"2024","journal-title":"Lancet HIV"},{"issue":"5","key":"2025111816250493000_R21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s10508-022-02310-x","article-title":"Changing levels of social engagement with gay men is associated with HIV related outcomes and behaviors: trends in Australian behavioral surveillance 1998\u20132020.","volume":"51","author":"Chan","year":"2022","journal-title":"Arch Sex Behav"},{"issue":"3","key":"2025111816250493000_R22","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed6030139","article-title":"Estimation of potential HIV transmission risk in recent anal intercourse events among men who have sex with men and transgender women in Bali, Indonesia.","volume":"6","author":"Bavinton","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"7","key":"2025111816250493000_R23","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s10508-024-02886-6","article-title":"Willingness to use long-acting injectable cabotegravir and associated factors among men who have sex with men in Guangxi, China.","volume":"53","author":"Liu","year":"2024","journal-title":"Arch Sex Behav"},{"issue":"3","key":"2025111816250493000_R24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s10900-023-01318-1","article-title":"Awareness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Nepal.","volume":"49","author":"Paudel","year":"2024","journal-title":"J Community Health"},{"key":"2025111816250493000_R25","unstructured":"NCHADS\/MoH-Cambodia. Assessment Report: The Acceptability and Feasibility of Long-Acting Injectable HIV Pre-Exposure Prophylaxis (Cab-LA) Among MSM, TGW and Service Providers In Cambodia;\u00a02023. Available at https:\/\/www.nchads.org\/wp-content\/uploads\/2023\/10\/Assessment-Report-CAB-LA_among_MSM_TGW-in_Cambodia.pdf"},{"issue":"7\u20138","key":"2025111816250493000_R26","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1080\/17441692.2016.1154085","article-title":"\u2018I am not a man\u2019: Trans-specific barriers and facilitators to PrEP acceptability among transgender women.","volume":"11","author":"Sevelius","year":"2016","journal-title":"Glob Public Health"},{"issue":"4","key":"2025111816250493000_R27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/trgh.2021.0192","article-title":"Unique HIV risk factors and prevention needs for transgender women and cisgender men who have sex with men in Bangkok, Thailand.","volume":"8","author":"Dear","year":"2023","journal-title":"Transgend Health"},{"issue":"1","key":"2025111816250493000_R28","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10352-w","article-title":"Anticipated facilitators and barriers for long-acting injectable antiretrovirals as HIV treatment and prevention in Vietnam: a qualitative study among healthcare workers.","volume":"24","author":"Dang","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2025111816250493000_R29","doi-asserted-by":"publisher","DOI":"10.1177\/00469580211017666","article-title":"Recommendations for increasing physician provision of pre-exposure prophylaxis: implications for medical student training.","volume":"58","author":"Cooper","year":"2021","journal-title":"Inquiry"},{"issue":"2","key":"2025111816250493000_R30","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1016\/S2214-109X(23)00536-3","article-title":"Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.","volume":"12","author":"Zhao","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"2","key":"2025111816250493000_R31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/cid\/ciad537","article-title":"Global HIV incidence analysis and implications for affordability using long-acting cabotegravir versus continuous and event-driven oral preexposure prophylaxis.","volume":"78","author":"Sharma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2025111816250493000_R32","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2468-2667(21)00112-2","article-title":"HIV pre-exposure prophylaxis: scaling up for impact now and in the future.","volume":"6","author":"Bavinton","year":"2021","journal-title":"Lancet Publ Health"},{"issue":"13","key":"2025111816250493000_R33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women.","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"2025111816250493000_R34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons.","volume":"392","author":"Kelley","year":"2024","journal-title":"N Engl J Med"},{"key":"2025111816250493000_R35","unstructured":"Departmental News. WHO announces the development of new guidelines for lenacapavir and updated HIV testing guidelines. Geneva: World Health Organization; 2025. Available at https:\/\/www.who.int\/news\/item\/06-01-2025-who-announces-the-development-of-new-guidelines-for-lenacapavir-and-updated-hiv-testing-guidelines"},{"key":"2025111816250493000_R36"},{"issue":"1","key":"2025111816250493000_R37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1904-5","article-title":"HIV epidemiology and responses among men who have sex with men and transgender individuals in China: a scoping review.","volume":"16","author":"Tang","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"7","key":"2025111816250493000_R38","doi-asserted-by":"publisher","DOI":"10.2196\/14230","article-title":"Using digital communication technology to increase HIV testing among men who have sex with men and transgender women: systematic review and meta-analysis.","volume":"22","author":"Veronese","year":"2020","journal-title":"J Med Internet Res"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25065\/1717887\/sh25065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25065\/1717887\/sh25065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:25:09Z","timestamp":1763501109000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/22\/6\/SH25065\/251924\/Preparing-for-next-generation-PrEP-awareness-and"}},"subtitle":[],"editor":[{"given":"Chunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1071\/sh25065","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"SH25065"}}